Opko Health and Entera Bio have announced a partnership and licence agreement to progress the development of the first oral ...

Investors who take an interest in OPKO Health, Inc. (NASDAQ:OPK) should definitely note that the Chairman & CEO, Phillip Frost, recently paid US$1.74 per share to buy US$348k worth of the stock.

HC Wainwright reiterated their buy rating on shares of OPKO Health (NASDAQ:OPK – Free Report) in a research report sent to investors on Wednesday morning,Benzinga reports. The brokerage currently has ...

(Reuters) -OPKO Health and Entera Bio are partnering to develop a once-daily pill for patients with obesity and other ...

Under the terms of the agreement, OPKO will accept 60% of the development costs, while Entera will shoulder 40%.

OPKO Health (NASDAQ: OPK) has recently received a number of price target changes and ratings updates: 3/19/2025 – OPKO Health had its “buy” rating reaffirmed by analysts at HC Wainwright. They now ...

In a regulatory filing, Opko Health (OPK) disclosed that its CEO Phillip Frost bought 200K shares of common stock on March 17th in a total ...

OPKO Health and Entera Bio, a developer of oral peptides and protein replacement therapies, entered into a license agreement ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Opko Health and Entera Bio entered into a collaboration and license agreement to advance a tablet aimed at addressing obesity, metabolic and fibrotic disorders.

Vertical Aerospace • EVTL-NYSE Buy • $3.39 on March 12 by Canaccord Genuity We are maintaining our Buy rating on shares of ...

(RTTNews) - OPKO Health (OPK) and Entera Bio have entered a collaboration and license agreement to develop the first oral dual agonist GLP-1/glucagon peptide for obesity, metabolic, and fibrotic ...